2024³â04¿ù26ÀÏfri
·Î±×ÀÎ | ȸ¿ø°¡ÀÔ
OFF
Æ®À§ÅÍ·Î º¸³»±â ½ÎÀÌ¿ùµå °ø°¨
±â»ç±ÛÈ®´ë ±â»ç±ÛÃà¼Ò ±â»ç½ºÅ©·¦ À̸ÞÀϹ®ÀÇ ÇÁ¸°Æ®Çϱâ
Comparison of Nonspherical Polyvinyl Alcohol Particles and Microspheres for Prostatic Arterial Embolization in Patients with Benign Prostatic Hyperpla
±èÇü°ï¡¤¹é¼ºÇö¡¤¹ÚÇü±Ù ±³¼ö(°Ç±¹´ëº´¿ø ºñ´¢±â°ú)
[ 2017³â 10¿ù 23ÀÏ 14½Ã 20ºÐ ]
Comparison of Nonspherical Polyvinyl Alcohol Particles and Microspheres for Prostatic Arterial Embolization in Patients with Benign Prostatic Hyperplasia.
Biomed Res Int. 2017;2017:8732351
Authors: Hwang JH, Park SW, Chang IS, Jung SI, Jeon HJ, Lho YS, Kim HG, Paick SH, Park HK
AbstractPURPOSE: To report early results following prostatic artery embolization (PAE) and compare outcomes between nonspherical polyvinyl alcohol (PVA) particles and microspheres to treat lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH).METHODS: PAE was performed in nine patients (mean age: 78.1 years) with symptomatic BPH. Embolization was performed using nonspherical PVA particles (250-355 μm) in four patients and microspheres (300-500 μm) in five patients.RESULTS: PAE was technically successful in all nine patients (100%). During a mean follow-up of 10.1 months, improvements in mean International Prostate Symptom Score (IPSS), Quality of Life (QoL), prostatic volume (total volume and transition zone), and peak urinary flow (Qmax) were 9.8 points, 2.3 points, 28.1 mL, 17.8 mL, and 4.5 mL/s, respectively. Clinical success was obtained in seven of nine patients (78%). Patients in the microsphere group showed greater improvement in IPSS, QoL, prostatic volume, and Qmax compared to patients in the nonspherical PVA particle group. However, significant difference was noted only in the prostatic volume.CONCLUSION: PAE is a feasible, effective, and safe treatment option for BPH with LUTS. Use of microspheres showed greater prostatic volume reduction compared to nonspherical PVA particles.
µ¥Àϸ®¸Þµð dailymedi@dailymedi.com
À̱âÀÚÀÇ ´Ù¸¥´º½ºº¸±â
¹«ÅëÀåÀÔ±Ý Á¤º¸ÀÔ·Â ÀÔ±ÝÀÚ¸í ÀԱݿ¹Á¤ÀÏÀÚ
(ÀÔ±ÝÇÏ½Ç ÀÔ±ÝÀÚ¸í + ÀԱݿ¹Á¤ÀÏÀÚ¸¦ ÀÔ·ÂÇϼ¼¿ä)
[°ü·Ã´º½º]
- °ü·Ã´º½º°¡ ¾ø½À´Ï´Ù.
Æ®À§ÅÍ·Î º¸³»±â ½ÎÀÌ¿ùµå °ø°¨
±â»ç±ÛÈ®´ë ±â»ç±ÛÃà¼Ò ±â»ç½ºÅ©·¦ À̸ÞÀϹ®ÀÇ ÇÁ¸°Æ®Çϱâ
¸íÁöº´¿ø, ͺ ÀÌ°ÇÈñ ȸÀå ÁÖÄ¡ÀÇ ÀÌ°­¿ì ±³¼ö(»ï¼º¼­¿ïº´¿ø ÀçÈ°ÀÇÇаú) ¿µÀÔ
´ëÀü¼º¸ðº´¿ø ±èµ¿±â¡¤À̵¿Ã¢ ±³¼ö, ´ëÇÑÀ̺ñÀÎÈÄ°úÇÐȸ ÃÖ¿ì¼ö ±¸¿¬»ó¡¤ÃÖ¿ì¼ö Æ÷½ºÅÍ»ó
Á¶Àç¿ì ±³¼ö(°í´ë±¸·Îº´¿ø Á¤Çü¿Ü°ú), ´ëÇÑ°ñÀýÇÐȸ ÃÖ´Ù³í¹®»ó
´ëÇÑÀÇ»çÇùȸ ºÎȸÀå ¹éÇö¿í¡¤Àǹ«ÀÌ»ç ¿Àµ¿È£¡¤Á¤º¸Åë½ÅÀÌ»ç À¯¼Ò¿µèâ
Çѱ¹Á¦¾à¹ÙÀÌ¿ÀÇùȸ ÀǾàÇ°±¤°í½ÉÀÇÀ§¿øȸ À§¿øÀå ±è¼ºÁø¡¤ºÎÀ§¿øÀå ÀÌÁØÈñ¡¤ÀåÃá°ï èâ
¹è±â¼ö ±³¼ö(¾ÆÁִ뺴¿ø ¼Ò¾Æû¼Ò³â°ú), Á¦100ȸ ¾î¸°À̳¯ ¿ÁÁ¶±ÙÁ¤ÈÆÀå
À̺´ÈÆ¡¤½ÉÀç¾Ó ±³¼öÆÀ(±æº´¿ø Á¤Çü¿Ü°ú), ´ëÇÑ°ñÀýÇÐȸ ¿ÃÇØ ¿ì¼ö ±¸¿¬»ó
³²°¡Àº ±³¼ö(°í´ë±¸·Îº´¿ø °¡Á¤ÀÇÇаú), Çѱ¹¿©ÀÚÀÇ»çȸ Á¦4ȸ ÀþÀºÀÇÇÐÀÚ Çмú»ó
±¹¸³Áß¾ÓÀÇ·á¿ø Áß¾ÓÀÀ±ÞÀÇ·á¼¾ÅÍÀå ±è¼ºÁß(Á¶¼±´ëº´¿ø ÀÀ±ÞÀÇÇаú ±³¼ö)
ÃÖÁ¤¿õ ¿µ°æÀÇ·áÀç´Ü ÀüÁÖº´¿ø ÀÌ»çÀå, ¾Æµ¿º¸È£»ç¾÷ ±â±Ý 4000¸¸¿ø
±è¿µÁÖ ±³¼ö(ÀÌ´ë¸ñµ¿º´¿ø »êºÎÀΰú), Á¦13ȸ Çѵ¶¿©ÀÇ»çÇмú´ë»ó
¹ÚÂùÈì ±³¼ö(ÇѸ²´ëÃáõ¼º½Éº´¿ø À̺ñÀÎÈÄ°ú), ´ëÇÑÀ̺ñÀÎÈÄ°úÇÐȸ Çмú»ó
Á¶¼öÁø ±³¼ö(ÇѸ²´ëµ¿Åº¼º½Éº´¿ø ½Å°æ°ú), Á¦26ȸ JWÁß¿ÜÇмú´ë»ó
¼­Á¤°Ç ¿¬¼¼¼­³»°ú ¿øÀå ÀåÀλó